Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men

Clinical Endocrinology

Volumn 45, Issue 1, 1996, Pages 61-71

  Jockenhovel F ^a,b   Vogel, E ^a   Kreutzer, M ^a   Reinhardt, W ^a   Lederbogen, S ^a   Reinwein, D ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANDROSTANOLONE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; OFLOXACIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPOGONADISM; INFECTION; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; DIHYDROTESTOSTERONE; DRUG IMPLANTS; ESTRADIOL; FOLLICLE STIMULATING HORMONE; HALF-LIFE; HUMANS; HYPOGONADISM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PATIENT SATISFACTION; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TIME FACTORS;

EID: 0029888841     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.1996.tb02061.x     Document Type: Article

References (41)

1. Ahmed, S.R., Boucher, A.E., Manni, A., Santen, R.J., Bartholomew, M. & Demers, L.M. (1988) Transdermal testosterone therapy in the treatment of male hypogonadism. Journal of Clinical Endocrinology and Metabolism, 66, 546-551.
2. Bals-Pratsch, M., Knuth, U.A., Yoon, Y.-D. & Nieschlag, E. (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet, 4, 943-946.
3. Bals-Pratsch, M., Langer, K., Place, V.A. & Nieschlag, E. (1988) Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinologica, 118, 7-13.
4. Behre, H.J.M. & Nieschlag, E. (1992) Testosterone buciclate (20-Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. Journal of Clinical Endocrinology and Metabolism, 75, 1204-1210.
5. Behre, H.J.M., Oberpenning, F. & Nieschlag, E. (1990) Comparative pharmacokinetics of androgen preparations: application of computer analysis and simulation. In Testosterone (eds E. Nieschlag & H.M. Behre), pp. 115-153. Springer Verlag, Berlin.
6. Belkien, L.D., Schürmeyer, T., Hano, R., Gunnarsson, P.O. & Nieschlag, E. (1985) Pharmacokinetics of 19-nortestosterone esters in normal men. Journal of Steroid Biochemistry, 22, 623-629.
7. Bhasin, S. (1992) Androgen treatment of hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 74, 1221-1225.
8. Bhasin, S., Swerdloff, R.S., Steiner, B., Peterson, M.A., Meridores, T., Galmirini, M., Pandian, M.R., Goldberg, R. & Berman, N. (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 74, 75-83.
9. Bishop, P.M.F. & Folley, S.J. (1951) Absorption of hormone implants in man. Lancet, ii, 229-232.
10. Biskind, G.R., Escamilla, .F. & Lisser, H. (1941) Treatment of. Eunuchoidism: implantation of testosterone compounds in cases of male eunuchoidism. Journal of Clinical Endocrinology, 1, 38-49.
11. Burris, A.S., Ewing, L.L. & Sherins, R.J. (1988) Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertility and Sterility, 50, 493-497.
12. Cantrill, J.A., Dewis, P., Large, D.M., Newman, M. & Anderson, D.C. (1984) Which testosterone replacement therapy? Clinical Endocrinology, 21, 97-107.
13. Conway, A.J., Boylan, L.M., Howe, C., Ross, G. & Handelsman, D.J. (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. International Journal of Andrology, 11, 247-264.
14. Cunningham, G.R., Cordero, . & Thornby, J.I. (1989) Testosterone replacement with transdermal therapeutic systems. Journal of the American Medical Association, 261, 2525-2530.
15. Cutler, .J. (1987) Definition of mean residence times in pharmacokinetics. Biopharmaceutics and Drug Disposition, 8, 87-97.
16. Díaz-Sánchez, V., Larrea, F., Ulloa-Aguirre, A., Garzo-Flores, J., Richards, . & Veayra, F. (1989) Absorption of dihydrotestosterone (DHT) after its intramuscular administration. Fertility and Sterility, 51, 493-497.
17. R testosterone transdermal system in previously untreated hypogonadal men. Proc. Am. Endocr. Soc. 77th Ann. Meet. P2-121.
18. Franchi, F., Luisi, M. & Kicovic, P.M. (1978) Long-term study of oral testosterone undecanoate in hypogonadal males. International Journal of Andrology, 1, 270-278.
19. Franchimont, P., Kicovic, P.M., Mattei, A. & Roulier, R. (1978) Effects of oral testosterone undecanoate in hypogonadal male patients. Clinical Endocrinology, 9, 313-320.
20. Handelsman, D.J., Conway, A.J. & Boylan, L.M. (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. Journal of Clinical Endocrinology and Metabolism, 71, 216-222
21. Heinzel, G., Woloszcak, R. & Thomann, P. (1993) Pharmacokinetic and pharmacodynamic data analysis system for the PC pp. 1.1-5.131. Gustav Fischer Verlag, Stuttgart, New York.
22. Horton, R., Shinsako, J. & Forsham, P.H. (1965) Testosterone production and metabolic clearance rates with volumes of distribution in normal adult men and women. Acta Endocrinologica, 48, 446-458.
23. Knuth, U.A., Behre, H.J.M., Belkien, L.D., Bents, H. & Nieschlag, E. (1985a) Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation. Fertility and Sterility, 44, 814-821.
24. Knuth, U.A., Behre, HJ.M., Belkien, L.D., Bents, H. & Nieschlag, E. (1985a) 19-Nortestosterone for male fertility regulation. In Male Contraception: Advances and Future (eds G.I. Zatuchni, A. Goldsmith & J.M. Spiler), pp. 320-328.
25. Mayer, P.R. & Brazzell, R.K. (1988) Application of statistical moment theory to pharmacokinetics. Journal of Clinical Pharmacology, 28, 481-483.
26. Meikle, A.W., Mazer, N.A., Moellmer, J.F., Stringham, J.D., Tolman, K.G., Sanders, S.W. & Odell, W.D. (1992) Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 74, 623-628.
27. Meikle, A.W., Stingham, J.D., Bishop, DT. & West, .W. (1988) Quantitating genetic and nongenetic factors influencing androgen production and clearance rates in men. Journal of Clinical Endocrinology and Metabolism, 67, 104-109.
28. Nankin, H.R. (1987) Hormone kinetics after transmuscular testosterone cypionate. Fertility and Sterility, 47, 1004-1009.
29. Nieschlag, E. & Behre, H.J.M. (1990) Pharmacology and clinical use of testosterone. In Testosterone (eds E. Nieschlag & H.M. Behre), pp. 92-114. Springer Verlag, Berlin.
30. Nieschlag, E., Cüppers, H.J., Wiegelmann, W. & Wickings, E.J. (1976) Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Hormone Research, 7, 1380-145.
31. Plymate, S.R., Leonard, J.M., Paulsen, C.A., Fariss, B.L. & Karpas, A.E. (1983) Sex hormone-binding globulin changes with androgen replacement. Journal of Clinical Endocrinology and Metabolism, 57, 645-648.
32. Reiter, T. (1965) Testosterone implantations: the method of choice for treatment of testosterone deficiency. Journal of American Geriatric Society, 13, 1003-1012.
33. Salehian, B., Wang, C., Davidson, T., Umana, V., Steiner, B., Peterson, P., Sinha-Hikim, I. & Swerdloff, R.S. (1994) Comparison of pharmacokinetics of testosterone (T) after sublingual testosterone cyclodextrin (SLT) or testosterone enanthate injections (TE). Clinical Research, 42, 74A.
34. Schulte-Beerbühl, M. & Nieschlag, E. (1980) Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertility and Sterility, 33, 201-203.
35. Schürmeyer, T. & Nieschlag, E. (1984) Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexane-carboxylate as assessed by serum and salivary testosterone levels in normal men. International Journal of Andrology, 7, 181-187.
36. Schürmeyer, T., Wickings, E.J., Freischem, C.W. & Nieschlag, E. (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinologica, 102, 456-462.
37. Skakkebaek, N.E., Bancroft, J., Davidson, D.W. & Warner, P. (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clinical Endocrinology, 14, 49-61.
38. Snyder, P.J. & Lawrence, D.A. (1980) Treatment of male hypogonadism with testosterone enanthate. Journal of Clinical endocrinology and Metabolism, 51, 1335-1339.
39. Stuenkel, C.A., Dudley, R.E. & Yen, S.S.C. (1991) Sublingual administration of testosterone-hydroxylpropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 72, 1054-1059.
40. Thom, M.H. & Studd, J.W.W. (1980) Hormone implantation. British Medical Journal, 848-850.
41. Tschöp, M., Dressendörfer, R.A., Behre, H.J.M., Nieschlag, E. & Strasburger, C.J. (1995) Monitoring of substitution therapy with testosterone buciclate in hypogonadal men by a time-resolved fluorescence immunoassay for salivary testosterone. Proceedings of the American Endocrinological Society, 77th Annual Meeting, P2-116.